GSC 000190
Alternative Names: GSC-000190Latest Information Update: 04 Jul 2024
At a glance
- Originator GeneScience Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action KIF18A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Preclinical trials in Solid tumours in China (unspecified route)
- 05 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical trial in Solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Genescience Pharmaceuticals plans a phase I trial for Solid tumour in second quater of 2024